Release of NAD ϩ during preparation of murine lymphocytes causes enzymatic ADP-ribosylation of cell-surface proteins on T cells, catalyzed by toxin-related ecto-ADP-ribosyltransferase, ARTC2. ADP-riboslyation activates the cytolytic P2X7 ion channel and affects, in particular, the vitality and function of Tregs and NKT cells. Here, we describe a simple method-injection of an ARTC2-blocking nanobody-to greatly improve Treg and NKT cell vitality and to preserve their function during in vitro assays and in adoptive-transfer experiments. Moreover, we present a method for the sorting of functional, primary NKT cells, based on coexpression of ARTC2 and NK1.1. Our results pave the way for the efficient ex vivo proliferation of Tregs and NKT cells and for new experimental and therapeutic uses of these important regulatory cells. J. Leukoc. Biol. 95: 543-549; 2014.
Introduction
The recovery of functional Treg subsets from lymphatic tissues is notoriously difficult. Impaired function of freshly prepared Tregs (CD4
ϩ Tregs) and NKT cells (CD3 ϩ NK1.1 ϩ NKT cells) can be attributed to enzymatic, NAD ϩ -dependent ADP-ribosylation of cell-surface proteins in response to NAD ϩ released from cells during isolation [1, 2] . Treg subsets express high levels of the toxin-related ARTC2 cell-surface enzyme and its major target, the cytolytic P2X7 ion channel [2, 3] . ADP-ribosylation of Arg125 induces gating of P2X7, causing influx of calcium and efflux of potassium ions (Fig. 1A) [4] . This activates a cascade of downstream effects, resulting in shedding of the protease-sensitive ecto-domains of CD27 and CD62L, externalization of phosphatidylserine, uptake of the DNA-binding dye PI, and ultimately, cell death [5] [6] [7] [8] . Preparation of cells from lymphatic organs is routinely carried out on ice (4°C) in an attempt to preserve the functional vitality of the isolated cells. Yet, ARTC2 is highly active at 4°C, and ADPribosylates cell-surface proteins even when cells are prepared on ice. Activation of P2X7, in contrast, requires a temperature range of 22°C-37°C [1] . Thus, the phenotypic and functional changes induced by ADP-ribosylation of P2X7 become visible only when cells are returned to 37°C, e.g., in vitro for functional assays or in vivo for adoptive-transfer studies.
Nanobodies are the smallest antigen-binding domains derived from heavy-chain antibodies naturally occurring in llamas [9 -11] . Their propensity to bind to functional crevices on proteins accounts for their capacity to act as potent enzyme inhibitors [12] . Their small size (15 kD) accounts for their excellent tissue penetration in vivo [13] . Here, we present a simple nanobody-based approach that prevents ADP-ribosylation of cell-surface proteins during preparation of primary T cells. We show that injecting 50 g of an ARTC2-blocking nanobody i.v. into mice, 15 min prior to death, greatly improves the recovery of functional Tregs and NKT cells from spleen and liver, respectively.
MATERIALS AND METHODS

Mice
ARTC2
Ϫ/Ϫ mice [14] and P2X7 Ϫ/Ϫ mice [15] (kindly provided by Chris Gabel, Pfizer, Ann Arbor, MI, USA) were backcrossed onto the C57BL/6J background for at least 12 generations. The diphtheria toxin receptor-GFP transgene from DEREG mice [16] (kindly provided by Tim Sparwasser, TWINCORE, Hannover, Germany) was backcrossed on ARTC2 Ϫ/Ϫ and P2X7 Ϫ/Ϫ mice, as described previously [2] . Mice were kept at the animal facility of the University Medical Center (UKE), and all experiments were performed with approval of the responsible regulatory committee.
Production and purification of nanobody s؉16a
Nanobody sϩ16a was selected from a phage-display library, generated from a llama, immunized with a cDNA expression vector for ARTC2, as described previously [17] . The coding region of sϩ16a was subcloned into the pCSE2.5 vector (kindly provided by Thomas Schirrmann, Technische Universität Braunschweig, Germany). Supernatants were harvested 5 days after transfection of this construct into HEK-6E cells (kindly provided by Ives Durocher, NRC, Ottawa, Ontario, Canada). His6x-tagged nanobodies were affinity-purified by immobilized metalaffinity chromatography on nickel-nitrilotriacetic acid columns (Sigma, St. Louis, MO, USA). Buffer was exchanged by gel filtration, and nanobodies were adjusted to a concentration of 1 mg/ml in PBS and stored at 4°C.
Nanobody injections
Purified nanobodies (50 g/200 l sterile saline) were injected i.v. using a 27-G needle and a 1-ml tuberculine syringe (Omnifix; B. Braun, Melsungen, Germany). Two common methods for i.v. injection were found to work equally well. For injection into the tail vein, mice were placed under an infrared lamp for 3 min and then transferred to a fixation tube. For retro-orbital injections [18] , mice were anesthesized briefly with isofluoran. Mice were killed by cervical dislocation, 15 min after nanobody injections.
Cell preparation
Single-cell suspensions were prepared from heparinized blood, spleen, pLNs, and liver. All preparation procedures were performed on ice. Blood was centrifuged, subjected to erythrocyte lysis (ACK lysis buffer, 155 mM NH 4 Cl, 10 mM KHCO 3 , 100 M EDTA, pH ϳ7.2), and washed once in PBS. Spleens and pLNs were gently minced through a Nytex membrane. Cells were filtered through a 70-m cell strainer (Falcon) and washed once in PBS supplemented with 1% FCS. Spleen cells were resuspended in 5 mL ACK lysis buffer, incubated for 5 min on ice, centrifuged, and washed once in PBS containing 1% FCS. Liver lobes were gently mashed through a metal sieve using a syringe piston. Purification of liver leukocytes was achieved by running a Percoll gradient using Easycoll separation medium (Biochrom, Merck Millipore, Berlin, Germany). To this end, cells were resuspended in 5 mL 40% Percoll/RPMI, layered onto 3 mL 66% Percoll/RPMI in a 15-mL Falcon tube, and centrifuged at 1600 rpm, 16°C, for 20 min without breaks. The interphase was collected, and cells were washed once in PBS supplemented with 1% FCS. Cells were resuspended in 2 mL ACK lysis buffer for 2 min to lyse erythrocytes. The tube was filled with 10 ml PBS containing 1% FCS, and cells were centrifuged at 1600 rpm for 5 min. Cells were washed once in PBS, supplemented with 1% FCS, and resuspended in RPMI medium (Invitrogen, Carlsbad, CA, USA), containing 1% L-glutamine (Invitrogen), 1% HEPES (Invitrogen), 1% Na-pyruvat (Invitrogen), 0.1 mM ␤-2-mercaptoethanol (Invitrogen), and 10% FCS. 
Flow cytometry and FACS
P2X7-dependent shedding of CD27 and uptake of PI
Loss of CD27 from the cell surface and uptake of PI were analyzed by flow cytometry. Cells were labeled with perCP-conjugated anti-CD27 mAb (Clone LG.3A10; BioLegend), resuspended in RPMI complete medium, and incubated at 4°C or 37°C for 15 min before flow cytometry. Uptake of PI was monitored after incubation of cells for the indicated times at 4°C or 37°C. PI (1 M) was added to the cells 5 min before flow cytometric analysis.
T suppressor assay
FACS-sorted Tregs and Tresp were washed once with PBS, and Tregs were resuspended in RPMI complete medium. Tresp were resuspended in 1 mL PBS in a 15-mL Falcon tube and stained with 4 M eFluor 670 (eBioscience) at room temperature for 4 min. Cells were then washed twice with 10 mL PBS ϩ 1% FCS and resuspended in 1 ml RPMI complete medium. Purified Tregs and eFluor 670 -labeled Tresp were cocultured for 72 h at the indicated ratios in a round-bottom, 96-well plate (Nunc, Denmark; 5ϫ10 4 Tresp/well) in the presence of anti-CD3 mAb (Clone 145-2C11; 0.1 g/ml) and 2 ϫ 10 5 allogeneic APCs (splenocytes of C57BL/6J-RAG1 Ϫ/Ϫ mice).
Cells were stained with anti-CD4 and analyzed by flow cytometry. The proliferation of the CD4 ϩ Tresp was quantified via the dilution of the eFluor 670 , using the proliferation tool of FlowJo, and is displayed as "% dividing cells".
NKT cell proliferation assay
Freshly prepared liver leukocytes were resuspended in 1 mL PBS in a 15-mL Falcon tube and stained with 4 M eFluor 670 (eBioscience) at room temperature for 4 min and then washed twice with 10 mL PBS ϩ 1% FCS. Cells were resuspended in RPMI complete medium at a concentration of 5 ϫ 10 5 cells/mL and transferred to a 96-well plate (100 l/well). Cells were incubated for 72 h in the presence of 1 g/mL ␣-GalCer (Avanti Polar Lipids, Alabaster, AL, USA). Cells were subsequently stained with PEconjugated, ␣-GalCer-loaded CD1d-tetramers, and cell proliferation of ␣-GalCer-tetramer ϩ NKT cells was measured via the dilution of eFluor 670 .
Intracellular cytokine staining
Cells were incubated in complete RPMI medium in the presence of 1 g/mL ␣-GalCer (Avanti Polar Lipids). After 12 h, BFA (10 g/mL) was added, and the incubation continued for 2 h. Cells were stained with antiCD3e and PE-conjugated, ␣-GalCer-loaded CD1d-tetramers for 30 min, washed, and fixed with 2% PFA for 10 min. Cells were then stained for 20 min with anti-IFN-␥, diluted in PBS containing 0.5% saponin, and analyzed by flow cytometry.
Adoptive-transfer experiments
Tregs were purified by FACS from spleen and pLNs of DEREG mice that had received an injection of nanobody sϩ16a or of PBS (control) 15 min prior to sacrifice. NKT cells were purified by FACS from livers of similarly treated WT mice. Cells from nanobody or PBS-injected mice were labeled with eFluor 670 or with eFluor 450 to be able to distinguish these cells after coadministration in vivo. The labeled cells were mixed in a 1:1 ratio, as verified by FACS analysis, and 5 ϫ 10 5 cells were injected i.v. into Rag1
mice. Mice were killed 24 h later, and spleen, pLNs, and blood were analyzed for the presence of transferred Tregs; liver and blood were analyzed for the presence of transferred NKT cells. The relative amounts of the transferred cell populations and absolute cell counts were determined by flow cytometry.
RESULTS AND DISCUSSION
Splenic Tregs and liver NKT cells respond to NAD
؉ released during cell preparation
Previous studies have shown that NAD ϩ is released during cell preparation and serves as a substrate for ARTC2 that activates P2X7 by ADP-ribosylation [1] . Most splenic Tregs (CD4 ϩ CD25 ϩ ) and liver NKT cells (CD3e ϩ NK1.1 ϩ ) express high levels of ARTC2 and P2X7 (Fig. 1B) . In contrast, thymic Tregs and NKT cells show little, if any, cell-surface expression of ARTC2 or P2X7 (Supplemental Fig. 1) .
To assess the impact of NAD ϩ released during cell preparation on spleen Tregs and liver NKT cells, we monitored P2X7-dependent loss of CD27 from the cell surface and staining by PI of freshly prepared splenocytes and liver lymphocytes upon incubation at 4°C versus 37°C. To allow better visualization and sorting of Tregs, we used DEREG mice that express GFP under control of the foxp3 promoter for some experiments [16] . We found that the majority of splenic Tregs (CD4 ϩ GFP ϩ ) and liver NKT cells (CD4 ϩ CD1d-tetramer ϩ ) from WT mice shed CD27 within 15 min of incubation at 37°C (Fig. 1C) . Analyses of cells from ARTC2 Ϫ/Ϫ and P2X7
Ϫ/Ϫ mice confirm that shedding of CD27 at 37°C depends on both of these proteins (Fig. 1C) . Furthermore, incubation of FACSsorted WT Tregs and NKT cells at 37°C, for up to 120 min, resulted in irreversible uptake of PI by the majority of these cells (Fig. 1D) . These results are consistent with the results of an earlier report, showing a high proportion of apoptotic NKT cells obtained from livers of WT but not of ARTC2 Ϫ/Ϫ or P2X7 Ϫ/Ϫ mice [19] .
Injection of the ARTC2-blocking nanobody s؉16a preserves the vitality of Tregs and NKT cells
On the basis of these observations, we hypothesized that preventing ARTC2-mediated ADP-ribosylation of P2X7 during cell preparation could be a means to preserve the vitality and function of primary WT Tregs and NKT cells. Recently, we generated a nanobody, designated sϩ16a, from an immunized llama that specifically and effectively blocks the enzymatic activity of ARTC2 ( Fig. 2A) [17] . The injection of 50 g of this nanobody i.v. into WT mice, 15 min before death, indeed, effectively prevented shedding of CD27 (Fig. 2B ) and uptake of PI (Fig. 2C ) by splenic Tregs and liver NKT cells.
Injection of the ARTC2-blocking nanobody s؉16a preserves the function of splenic Tregs in vitro
To assess how ADP-ribosylation of P2X7 during cell preparation affects the function of primary Tregs during in vitro experiments, we analyzed the suppressive function of splenic (Fig. 3) , consistent with the notion that ARTC2-catalyzed ADP-ribosylation of P2X7 during cell preparation affects the function of Tregs. To assess whether injection of the ARTC2-blocking nanobody sϩ16a could preserve the function of WT Tregs in vitro, we compared Tregs derived from sϩ16a-injected versus mock-injected WT mice in an in vitro T suppression assay. Injection of nanobody sϩ16a, indeed, resulted in a markedly improved, suppressive activity of WT Tregs (Fig. 3) , i.e., to a level comparable with that of ARTC2 Ϫ/Ϫ or P2X7 Ϫ/Ϫ Tregs. Thus, the simple injection of an ARTC2-blocking nanobody can preserve the inherent functionality of WT Tregs during ex vivo suppression assays.
Injection of the ARTC2-blocking nanobody s؉16a preserves the function of liver NKT cells in vitro
To assess how ARTC2-catalyzed ADP-ribosylation of P2X7 during cell preparation affects the function of primary NKT cells during in vitro experiments, we analyzed the proliferation and IFN-␥ production of liver NKT cells in response to stimulation with ␣-GalCer. Comparative analyses of NKT cells obtained from WT, ARTC2 Ϫ/Ϫ , and P2X7 Ϫ/Ϫ mice revealed a robust proliferation of NKT cells derived from ARTC2 Ϫ/Ϫ or P2X7 Ϫ/Ϫ mice, as evidenced by dilution of the e-Fluor dye and an increase in the relative cell number (Fig. 4A) . In contrast, NKT cells from WT mice showed some dilution of e-Fluor dye but little, if any, increase in the relative cell number. These results are consistent with the notion that ADP-ribosylation of P2X7 during cell preparation impairs the capacity of NKT cells to respond to ␣-GalCer.
Furthermore, we analyzed whether injection of nanobody sϩ16a could preserve proliferation of WT NKT cells in vitro. To this end, we compared ␣-GalCer-induced proliferation of NKT cells obtained from sϩ16a-treated versus mock-treated mice. Injection of nanobody sϩ16a, indeed, resulted in a markedly increased amount of proliferating WT NKT cells (Fig. 4A) 
Coexpression of ARTC2 and NK1.1 allows sorting of functional NKT cells from nanobody-injected mice
NKT cells express TCRs that recognize glycolipids presented by the MHC I-like CD1d cell-surface protein [20] . They can be distinguished from conventional T cells on the basis of their expression of CD3 or TCR-␤ chain and NK1.1. Use of antibodies directed against the TCR complex during cell sorting, however, may affect subsequent responses to TCR triggering. We noticed that NKT cells could also be distinguished from conventional T cells by their high expression of ARTC2. FACS analysis revealed that NK1.1 ϩ ARTC2 hi cells correspond to NK1.1 ϩ CD3 int cells (Supplemental Fig. 2A ). We hypothesized that functional NKT cells could be sorted from sϩ16a-treated mice using an anti-ARTC2 mAb that recognizes an ARTC2 epitope, independent of sϩ16a binding, thereby avoiding interference with TCR components. Flow cytometric cell sorting of NK1.1 ϩ ART2 ϩ cells revealed that Ͼ90% of the purified cells were CD1d-tetramer ϩ (Supplemental Fig. 2B ). When combined with an injection of nanobody sϩ16a before death, ARTC2 ϩ NK1.1 ϩ -purified NKT cells responded with robust IFN-␥ production to ␣-GalCer stimulation (59% IFN-␥ ϩ cells), whereas NKT cells from mock-treated mice showed little if any IFN-␥ response (2% IFN-␥ ϩ cells; Fig. 5A ). To determine whether the mode of sorting might affect the function of NKT cells, we compared the IFN-␥ response of NKT cells sorted via ARTC2 versus NKT cells sorted using a nonactivating antibody against TCR-␤. In both cases, a strong IFN-␥ response was seen in NKT cells from sϩ16a-treated mice but not from control mice (Fig. 5B ).
Tregs and NKT cells from nanobody-injected mice survive better than cells from untreated WT mice upon adoptive transfer into Rag
؊/؊ mice
In addition to in vitro assays, purified Tregs and NKT cells are commonly used in adoptive-transfer experiments for functional analyses in vivo [21] [22] [23] . Considering our findings-that simply incubating primary Tregs and NKT cells at 37°C results in shedding of cell-surface proteins and impaired vitality in vitro-we inferred that such events probably also occur in vivo upon injection of purified Tregs or NKT cells into mice. Moreover, we hypothesized that Tregs and NKT cells purified from WT animals after injection of nanobody sϩ16a would exhibit enhanced vitality in vivo upon adoptive transfer into mice, as they do in vitro.
To test this hypothesis for Tregs, we coinjected Tregs purified from sϩ16a-treated and mock-treated mice in a 1:1 ratio into Rag1 Ϫ/Ϫ mice. Each Treg population was labeled differently with a fluorescent dye and could thus, readily be distinguished in vivo. Twenty-four hours after cotransfer of Tregs, mice were killed, and Treg frequencies in spleen, pLNs, blood, and liver were determined. The recovered Tregs contained approximately fourfold more cells from sϩ16a-treated mice than from mock-treated mice at each of these sites (Fig. 6A) . Therefore, we conclude that a simple injection of nanobody sϩ16a protects Tregs from the deleterious effects of NAD ϩ -dependent ADP-ribosylation of P2X7, thereby improving Treg functionality in adoptive-transfer experiments.
To test our hypothesis for NKT cells, we cotransferred NKT cells purified from sϩ16a-treated and mock-treated mice in a 1:1 ratio into Rag1 Ϫ/Ϫ mice. Twenty-four hours after injection, only NKT cells from sϩ16a-treated mice were detectable in blood and liver (Fig. 6B) . Thus, injection of sϩ16a provides a novel, simple protocol to enable the survival of adoptively transferred, naive NKT cells in vivo.
In summary our findings demonstrate that the functional integrity of primary murine Tregs and NKT cells can be maintained by preventing ARTC2-mediated ADP-ribosylation of P2X7 during cell preparation. A single injection of nanobody sϩ16a, 15 min before death, greatly enhances the survival and function of Tregs and NKT cells in vitro and in adoptive-transfer experiments in vivo. These findings underscore the potential of nanobody sϩ16a as a valuable tool to improve and facilitate research on Tregs and NKT cells and pave the way for new experimental and therapeutic approaches using these cells.
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